سعر اندوريفابان 15 مجم 20 قرص 2026

Tablets containing rivaroxaban 15 mg (Al Andalous Pharmaceutical Industries), an oral direct factor Xa inhibitor anticoagulant; 20 tablets per pack.

• Prevention of stroke and systemic embolism in non-valvular atrial fibrillation with one or more risk factorsPopulation: AdultsEuropean Medicines Agency (EMA)
• Treatment of DVT and PE and prevention of recurrent DVT and PEPopulation: AdultsEuropean Medicines Agency (EMA)
• Treatment of VTE and prevention of VTE recurrence after at least 5 days of parenteral anticoagulationPopulation: Children and adolescents <18 years weighing 30-50 kgEuropean Medicines Agency (EMA)

• Bleeding is the most commonly reported adverse reaction (most frequent: epistaxis 4.5% and gastrointestinal haemorrhage 3.8%); anaemia, dizziness, headache, hypotension, GI upset, pruritus/rash, pain in extremity, renal impairment and fever are also common; syncope is uncommon.International label, same formulation · European Medicines Agency (EMA)

• Hypersensitivity to rivaroxaban or any excipient; active clinically significant bleeding.International label, same formulation · European Medicines Agency (EMA)
• Lesions or conditions at significant risk of major bleeding (e.g., recent GI ulceration, malignancy at high bleeding risk, recent brain/spinal injury or surgery, intracranial haemorrhage, oesophageal varices, vascular malformations).International label, same formulation · European Medicines Agency (EMA)
• Concomitant treatment with any other anticoagulant except when switching or with unfractionated heparin to keep catheters open.International label, same formulation · European Medicines Agency (EMA)

• Bleeding risk: monitor for signs of bleeding; use with caution in conditions with increased haemorrhage risk; concomitant NSAIDs, antiplatelets, SSRIs/SNRIs increase bleeding risk.International label, same formulation · European Medicines Agency (EMA)
• Not recommended with systemic azole antimycotics (e.g., ketoconazole, itraconazole, voriconazole, posaconazole) or HIV protease inhibitors (strong CYP3A4 and P-gp inhibitors).International label, same formulation · European Medicines Agency (EMA)
• Not recommended in patients with prosthetic heart valves (including TAVR) or triple-positive antiphospholipid syndrome; spinal/epidural haematoma risk with neuraxial anaesthesia or puncture - observe timing recommendations.International label, same formulation · European Medicines Agency (EMA)

• Strong CYP3A4 and P-gp inhibitors (azole antimycotics such as ketoconazole, itraconazole, voriconazole, posaconazole; HIV protease inhibitors such as ritonavir)Markedly increased rivaroxaban levels and bleeding risk; not recommended.European Medicines Agency (EMA)
• Other anticoagulants (e.g., enoxaparin, warfarin)Additive anticoagulant effect; contraindicated except when switching.European Medicines Agency (EMA)
• NSAIDs, acetylsalicylic acid, other platelet aggregation inhibitors, SSRIs/SNRIsIncreased bleeding risk; use with care.European Medicines Agency (EMA)

• Contraindicated during pregnancy (reproductive toxicity, intrinsic bleeding risk and placental passage); women of childbearing potential should avoid becoming pregnant during treatment.International label, same formulation · European Medicines Agency (EMA)
• Contraindicated during breast-feeding; decide whether to discontinue breast-feeding or treatment.International label, same formulation · European Medicines Agency (EMA)

• Rivaroxaban: Highly selective direct factor Xa inhibitor with oral bioavailability; inhibition of factor Xa interrupts the intrinsic and extrinsic coagulation pathways, inhibiting thrombin formation and thrombus development; does not inhibit thrombin and has no demonstrated effect on platelets (EU SmPC).